Drug Approval | March 11, 2023
USFDA completes inspection of Lupin’s Vizag facility
The inspection concluded with no observations
The inspection concluded with no observations
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
The company will engage with the agency to resolve the import alert at the earliest.
Subscribe To Our Newsletter & Stay Updated
